

**Bayer HealthCare  
Pharmaceuticals****RECEIVED  
CENTRAL FAX CENTER  
JUL 14 2006**

To Commissioner for Patents  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

Fax (571) 273-8300 Pages 3 (including cover sheet)  
Date July 14, 2006  
From Susan M. Pellegrino  
Fax (203) 812-6459 Tel. (203) 812-6450  
Re U.S. Patent Application Serial No.: 10/618,126

Bayer Pharmaceuticals  
Corporation

400 Morgan Lane  
West Haven, CT 06516

Phone: (203) 812-6450  
Fax: (203) 812-6459

E-mail:  
susan.pellegrino.b@bayer.com

For U.S. Patent Application Serial No. 10/618,126

- 1) Response to Office Action mailed on June 30, 2006
- 2) Certificate of Transmission under 37 CFR 1.8
- 3) Fax Cover Sheet

If you have any problems with the attached facsimile call (203) 812-6450.

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND EXEMPT FROM DISCLOSURE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AN EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERING THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT THE PRIVILEGED OR CONFIDENTIAL NATURE OF THIS MESSAGE IS NOT WAIVED BY INADVERTENT DISCLOSURE. ANY DISSEMINATION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

RECEIVED  
CENTRAL FAX CENTER

JUL 14 2006

PTO/SB/97 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Certificate of Transmission under 37 CFR 1.8**

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on July 14, 2006

Date

  
\_\_\_\_\_  
SignatureSusan M. Pellegrino, Reg. No. 48,972

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

For U.S. Patent Application Serial No. 10/618,126

- 1) Reply to Office Action mailed on June 30, 2006
- 2) Certificate of Transmission under 37 CFR 1.8
- 3) Fax Cover Sheet

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Attorney Docket No. MSB 7295

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTER  
JUL 14 2006

In re Patent Application of Froland, et al.

Serial No.: 10/618,126

Group Art Unit: 1646

Filed: July 11, 2003

Examiner: Michael D. Pak

For: Pituitary Adenylate Cyclase Activating Peptide (PACAP) Receptor (VPAC2) Agonists and Their Pharmacological Methods of Use

## CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being facsimile transmitted to the U.S. Patent and Trademark Office at (571) 273-8300.

Date: July 14, 2006

  
Susan M. Pellegrino

## RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


This is in response to the Office Action mailed June 30, 2006. In response to the restriction requirement, applicants elect the claims of restriction Group I, claims 1, 7, and 8, directed to a polypeptide, for further prosecution in this application. In addition, Applicants elect SEQ ID NO: 115 as the sequence for further prosecution in this application; for claim 14, Applicants elect hepatic glucose output lowering compounds; and for claims 16-53, Applicants elect type 2 diabetes.

In addition, Applicants would like to thank Examiner Pak for the teleconference to discuss the restriction requirement.

If there are any fees due in connection with the filing of the present response, please charge the fees to undersigned's Deposit Account No. 13-3372. If a fee is required for an extension of time not accounted for, such an extension is requested and the fee should also be charged to undersigned's deposit account.

Respectfully submitted,

Date: July 14, 2006

Bayer Pharmaceuticals Corporation  
400 Morgan Lane  
West Haven, CT 06516  
Telephone: (203) 812-6450  
Susan M. Pellegrino  
Attorney for Applicants  
Reg. No. 48,972